ClinicalTrials.gg
CompletedNCT06996184Updated Nov 21, 2025

Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults

A Phase 1 interventional study of Vamifeport (PR formulation) in Healthy Volunteers, sponsored by CSL Behring. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a phase I, single-center, randomized, open-label, single-dose, 2-way, 2-period, crossover study to evaluate the effect of food on the pharmacokinetics (PK) of vamifeport prolonged-release (PR) formulation in healthy adult participants. Participants will be randomly allocated to one of two treatment sequences.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • •Aged greater than or equal to (>=) 18 to less than or equal to (\<=) 60 years at the time of providing written .
  • •Healthy, as determined by the investigator based on review of defined assessments during Screening.
  • •Body weight between 50 and 100 kilogram (kg) (inclusive) and within the range 18.0 to 30.0 kg per square metre (kg/m2) (inclusive) at Screening and Day - 1.

Exclusion criteria

Exclusion Criteria:

  • •Any abnormal means of triplicate 12-lead finding at Screening or Day - 1 (as deemed by the investigator).
  • •Serum ferritin of less than (\<) 30 nanograms per milliliter (ng/mL) or greater than (>) 300 ng/mL for assigned male at birth (AMAB) participants or \< 16 ng/mL or > 300 ng/mL for assigned female at birth (AFAB) participants at Screening or Day - 1.
  • • \< 13 gram per deciliter (g/dL) (8.1 millimole per liter [mmol/L]) for AMAB participants or \< 12 g/dL (7.5 mmol/L) for AFAB participants at Screening or Day - 1.
  • •Blood draw or donation of blood (>= 450 mL) within 3 months before Screening, plasma donation from 2 weeks before Screening, or donation from 6 weeks before Screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Sequence 1: Vamifeport Fasted then Fed

    In sequence 1, eligible participants assigned to sequence 1 will receive a single vamifeport dose on an empty stomach on Day 1 (fasted condition), undergo a washout period, and then receive a single vamifeport dose after a standardized high-fat meal (fed condition) on Day 6.

    Drug: Vamifeport (PR formulation)

  • Experimental
    Sequence 2: Vamifeport Fed then Fasted

    In sequence 2, eligible participants assigned to sequence 2 will receive a single vamifeport dose after a standardized high-fat meal on Day 1 (fed condition), undergo a washout period, and then receive a single vamifeport dose on an empty stomach (fasted condition) on Day 6.

    Drug: Vamifeport (PR formulation)

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) of vamifeport

    Time frame: 0-96 hours after dose

  2. AUC from time zero extrapolated to infinity (AUC0-inf) of vamifeport

    Time frame: 0-96 hours after dose

  3. Maximum observed plasma concentration (Cmax) of vamifeport

    Time frame: 0-96 hours after dose

Secondary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs) overall, by severity, seriousness, and relationship to vamifeport

    Time frame: Up to Day 13 (+/- 2 days)

  2. Percentage of participants with TEAEs overall, by severity, seriousness, and relationship to vamifeport

    Time frame: Up to Day 13 (+/- 2 days)

  3. Number of participants with clinically significant changes from baseline in clinical laboratory safety tests (biochemistry, hematology, and urinalysis), 12-lead electrocardiogram (ECG), and vital signs, reported as TEAEs

    Time frame: Up to Day 13 (+/- 2 days)

  4. Percentage of participants with clinically significant changes from baseline in clinical laboratory safety tests (biochemistry, hematology, and urinalysis), 12-lead ECG, and vital signs, reported as TEAEs

    Time frame: Up to Day 13 (+/- 2 days)

  5. Time of the maximum observed plasma concentration (Tmax) of vamifeport

    Time frame: 0-96 hours after dose

  6. Apparent terminal disposition phase plasma half life (t1/2) of vamifeport

    Time frame: 0-96 hours after dose

  7. Apparent terminal disposition rate constant (λz) of vamifeport

    Time frame: 0-96 hours after dose

  8. Apparent total clearance (CL/F) of vamifeport

    Time frame: 0-96 hours after dose

  9. Apparent volume of distribution (V/F) of vamifeport

    Time frame: 0-96 hours after dose

  10. Percentage of AUC due to extrapolation from the last quantifiable concentration to infinity (%AUCextrap) of vamifeport

    Time frame: 0-96 hours after dose

  11. Time of the last quantifiable concentration (Tlast) of vamifeport

    Time frame: 0-96 hours after dose

  12. The time taken for vamifeport to appear in the systemic circulation following administration (Tlag), when applicable

    Time frame: 0-96 hours after dose

  13. AUC from time zero to 12 hours (AUC0-12) and 24 hours (AUC0-24) of vamifeport

    Time frame: 0-12 hours post-dose and 0-24 hours after dose

  14. Plasma concentration of vamifeport

    Time frame: At 12 hours and 24 hours after dose

07

Study locations

1 site
  • Investigator Site 82600083
    Leeds, West Yorkshire LS11 9E, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jul 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
May 27, 2025
Primary completionActual
Jul 1, 2025
CompletionActual
Jul 4, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06996184
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
May 30, 2025
Start date
May 27, 2025
Primary completion
Jul 1, 2025
Completion
Jul 4, 2025
Last update
Nov 21, 2025

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VIT-2763

Start the discussion